Home › Cancro del polmone non a piccole cellule › Arkansas › Little Rock
Studi clinici su Cancro del polmone non a piccole cellule a Little Rock, AR
13 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi a Little Rock e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
In reclutamentoFase 2
- University of Arkansas for Medical Sciences /ID# 272923, Little Rock
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
In reclutamentoFase 3
- UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060), Little Rock
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
In reclutamentoFase 2
- CARTI Cancer Center, Little Rock
Pan-tumor MRD Study
In reclutamentoStudio osservazionale
- CARTI, Little Rock
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
In reclutamentoFase 3
- Research Site, Little Rock
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
In reclutamentoFase 2
- Research Site, Little Rock
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
In reclutamentoFase 3
- CARTI Cancer Center ( Site 0006), Little Rock
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
In reclutamentoFase 3
- University of Arkansas for Medical Sciences, Little Rock
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- University of Arkansas, Little Rock
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
In reclutamentoFase 2
- University of Arkansas for Medical Sciences, Little Rock
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- University of Arkansas for Medical Sciences, Little Rock
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- University of Arkansas for Medical Sciences, Little Rock
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Little Rock
Studi su Cancro del polmone non a piccole cellule in altre città
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Altri studi a Little Rock
- Schizofrenia19 studi
- Cancro (tutti i tipi)14 studi
- Disturbo depressivo maggiore14 studi
- Leucemia mieloide acuta13 studi
- Obesità11 studi
- Cancro dell'endometrio10 studi
- Depressione10 studi
- Diabete di tipo 210 studi
- Cancro ai polmoni9 studi
- Malattie cardiovascolari9 studi
- Cancro della vescica9 studi
- Insufficienza cardiaca9 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.